Patient Information Leaflet
Signifor 10mg powder and solvent for injection
Signifor 20mg powder and solvent for injection
Signifor 30mg powder and solvent for injection
Signifor 40mg powder and solvent for injection
Signifor 60mg powder and solvent for injection
pasireotide
Read this leaflet carefully before you start using this medicine because it contains important information for you.
1.What isSigniforand what it is used for
2.What you need to know before starting to useSignifor
3.How to useSignifor
4.Possible side effects
5.Storage ofSignifor
6.Contents of the pack and additional information
Signifor is a medication that contains the active ingredient pasireotide. It is used to treat acromegaly in adult patients. It is also used to treat Cushing's disease in adult patients for whom surgery is not an option or has failed.
Acromegaly
Acromegaly is caused by a type of tumor called a pituitary adenoma, which appears in the pituitary gland at the base of the brain. The adenoma causes the body to produce an increased amount of hormones that control tissue, organ, or bone growth, resulting in an increase in the size of bones and tissues, especially in the hands and feet.
Signifor reduces the production of these hormones and possibly also the size of the adenoma. As a result, it reduces the symptoms of acromegaly, which include headache, increased sweating, numbness in the hands and feet, fatigue, and joint pain.
Cushing's Disease
Cushing's disease is caused by an enlargement of the pituitary gland (a gland located at the base of the brain) called a pituitary adenoma. This causes the body to produce an increased amount of a hormone called adrenocorticotropic hormone (ACTH), which in turn causes an increase in the production of another hormone called cortisol.
The human body naturally produces a substance called somatostatin, which blocks the production of certain hormones, including ACTH. Pasireotide works in a very similar way to somatostatin. Signifor is therefore able to block the production of ACTH, helping to control the overproduction of cortisol and improve the symptoms of Cushing's disease.
If you have any doubts about how Signifor works or why you have been prescribed this medication, consult with your doctor.
No use Signifor:
Advertencias y precauciones
Consult your doctor before starting to use Signifor if you suffer or have ever suffered from:
Durante su tratamiento con Signifor
Niños y adolescentes
Do not give this medication to children and adolescents under 18years because there are no available data in this age group.
Otros medicamentos y Signifor
Signifor may affect the way other medications work. If you are taking other medications at the same time as Signifor (including over-the-counter medications), your doctor may need to monitor your heart more closely or change the dose of Signifor or the other medications. Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. Especially, inform your doctor if you are taking:
Embarazo, lactancia y fertilidad
Consult your doctor or pharmacist before using any medication.
Conducción y uso de máquinas
Signifor may have a small effect on your ability to drive and use machines, as some of the adverse effects you may experience while taking Signifor, such as headache, dizziness, and fatigue, may reduce your ability to drive and use machines safely.
Información importante sobre alguno de los componentes de Signifor
Signifor contains less than 1mmol of sodium (23mg) per dose; this is, essentially“exempt from sodium”.
This medication will only be administered by a trained healthcare professional.
How much Signifor to use
Acromegaly
The recommended starting dose of Signifor in acromegaly is 40 mg every 4 weeks. After starting treatment, your doctor may reevaluate your dose. This may involve measuring growth hormone or other hormone levels in your body. Depending on the results and how you feel, it may be necessary to reduce or increase the dose of Signifor administered in each injection. The dose should not exceed 60 mg. If you have liver disease before starting treatment with Signifor, your doctor may decide to start treatment with a dose of 20 mg.
Cushing's disease
The normal starting dose of Signifor in Cushing's disease is 10 mg every 4 weeks. After starting treatment, your doctor may review the dose. This may involve measuring cortisol levels in the blood or urine. Depending on the results and how you feel, the dose of Signifor administered in each injection may be reduced or increased. The dose should not exceed 40 mg.
Your doctor will regularly monitor how you respond to treatment with Signifor and decide what dose is best for you.
How to use Signifor
Your doctor or nurse will administer Signifor. If you have any doubts, consult your doctor, nurse, or pharmacist.
Signifor is used by intramuscular injection. This means it is injected through a needle into the muscles of your buttocks.
For how long to use Signifor
This is a long-term treatment, possibly lasting years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. Your treatment with Signifor should continue as long as your doctor tells you it is necessary.
If you stop using Signifor
If you stop your treatment with Signifor, your symptoms may return. Therefore, do not stop your treatment with Signifor unless your doctor tells you to.
If you have any other questions about using this medication, ask your doctor, nurse, or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious. Inform your doctor immediately if you experience any of the following side effects:
Very common (may affect more than 1 in 10 patients)
Common (may affect up to 1 in 10 patients)
Other side effects of Signifor may include:
Very common (may affect more than 1 in 10 patients)
-Diarrhea
Common (may affect up to 1 in 10 patients)
Rare (may affect up to 1 in 100 patients)
Unknown frequency (cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Composition of Signifor
Signifor 10mg: each vial contains 10mg of pasireotide (as pasireotide pamoate)
Signifor 20mg: each vial contains 20mg of pasireotide (as pasireotide pamoate)
Signifor 30mg: each vial contains 30mg of pasireotide (as pasireotide pamoate)
Signifor 40mg: each vial contains 40mg of pasireotide (as pasireotide pamoate)
Signifor 60mg: each vial contains 60mg of pasireotide (as pasireotide pamoate)
Appearance of Signifor and contents of the pack
Signifor powder is a light yellow to yellow powder in a vial. The solvent is a transparent, colourless to slightly yellow or slightly brown solution in a pre-filled syringe.
Signifor 10mg is available in single-dose packs containing a vial of powder with 10mg of pasireotide and a pre-filled syringe with 2ml of solvent.
Signifor 20mg is available in single-dose packs containing a vial of powder with 20mg of pasireotide and a pre-filled syringe with 2ml of solvent.
Signifor 30mg is available in single-dose packs containing a vial of powder with 30mg of pasireotide and a pre-filled syringe with 2ml of solvent.
Signifor 40mg is available in single-dose packs containing a vial of powder with 40mg of pasireotide and a pre-filled syringe with 2ml of solvent.
Signifor 60mg is available in single-dose packs containing a vial of powder with 60mg of pasireotide and a pre-filled syringe with 2ml of solvent.
Each single-dose pack contains the vial and the pre-filled syringe in a blister pack sealed with an adapter to the vial and a safety needle.
Signifor 40mg and Signifor 60mg are also available in multi-dose packs containing 3intermediate packs.
It may be that, in your country, only some doses and some pack sizes are marketed.
Marketing authorisation holder
Recordati Rare Diseases
Immeuble Le Wilson
70 avenue du Général de Gaulle
92800 Puteaux
France
Responsible for manufacturing
Recordati Rare Diseases
Immeuble Le Wilson
70 avenue du Général de Gaulle
92800 Puteaux
France
Recordati Rare Diseases
Eco River Parc
30 rue des Peupliers
92000 Nanterre
France
You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien Recordati Tél/Tel: +32 2 46101 36 | Lietuva Recordati AB. Tel: + 46 8 545 80 230 Švedija |
???????? Recordati Rare Diseases Te?.: +33 (0)1 47 73 64 58 ??????? | Luxembourg/Luxemburg Recordati Tél/Tel: +32 2 46101 36 Belgique/Belgien |
Ceská republika Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francie | Magyarország Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Franciaország |
Danmark Recordati AB. Tlf:+ 46 8 545 80 230 Sverige | Malta Recordati Rare Diseases Tel: +33 1 47 73 64 58 Franza |
Deutschland Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 | Nederland Recordati Tel: +32 2 46101 36 België |
Eesti Recordati AB. Tel: + 46 8 545 80 230 Rootsi | Norge Recordati AB. Tlf: + 46 8 545 80 230 Sverige |
Ελλ?δα Recordati Hellas Τηλ: +30 210 6773822 | Österreich Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 Deutschland |
España Recordati Rare Diseases Spain S.L.U. Tel: + 34 91 659 28 90 | Polska Recordati Rare Diseases Tel: +33 (0)1 47 7364 58 Francja |
France Recordati Rare Diseases Tél: +33 (0)1 47 73 64 58 | Portugal Jaba Recordati S.A. Tel: +351 21 432 95 00 |
Hrvatska Recordati Rare Diseases Tél: +33 (0)1 47 73 64 58 Francuska | România Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Franta |
Ireland Recordati Rare Diseases Tél: +33 (0)1 47 73 64 58 France | Slovenija Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 Francija |
Ísland Recordati AB. Simi: + 46 8 545 80 230 Svíþjóð | Slovenská republika Recordati Rare Diseases Tel:+33 (0)1 47 73 64 58 Francúzsko |
Italia Recordati Rare Diseases Italy Srl Tel: +39 02 487 87 173 | Suomi/Finland Recordati AB. Puh/Tel : +46 8 545 80 230 Sverige |
Κ?προς Recordati Rare Diseases Τηλ: +33 1 47 73 64 58 Γαλλ?α | Sverige Recordati AB. Tel : +46 8 545 80 230 |
Latvija Recordati AB. Tel: + 46 8 545 80 230 Zviedrija | United Kingdom (Northern Ireland) Recordati Rare Diseases UK Ltd. Tel: +44 (0)1491 414333 |
Last update of this leaflet:
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu.There are also links to other websites on rare diseases and orphan medicines.
This information is intended solely for healthcare professionals:
INSTRUCTIONS FOR USE OF SIGNIFOR POWDER AND SOLVENT FOR INJECTABLE SUSPENSION
ONLY FOR INTRAMUSCULAR DEEP INJECTION
ATTENTION: In the process of reconstituting Signifor, there are two critical steps.If they are not performed correctly, this could mean that the injection is not administered properly.
|
The injection kit includes:
aA vial containing the powder
bA pre-filled syringe containing the solvent
cAn adapter to the vial for reconstituting the medicine
dA safety needle (20Gx1,5”)
Follow the detailed instructions below to ensure the proper reconstitution of Signifor powder and solvent for injectable suspension before intramuscular deep injection.
Signifor suspension should only be prepared immediately before administration.
Signifor should only be administered by a healthcare professional with experience.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.